Avaxim 0.5ml Vaccine

Prevention of Hepatitis A

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Avaxim 0.5 ml vaccine. But they disappear within a few days naturally as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Avaxim 0.5 ml vaccine are: Fatigue Headache Irritability Fever loss of appetite Nausea Pain, redness or swelling at injection site

The Avaxim 0.5 ml vaccine contains inactivated hepatitis A virus and is meant for children in the age group 12 months to 15 years. The single 0.5 ml dose is given intramuscularly. For children above 2 years, the vaccine is administered in the deltoid muscle of the upper arm, while for children under 2 years of age, the injection is given in the anterolateral aspect of the thigh.  A booster dose of 0.5 ml is recommended for long-term protection, which should be given between 6 and 36 months after the initial dose of vaccination. These two doses provide long-lasting immunity for at least 20 years. The Avaxim 0.5 ml vaccine should not be self-administered; it should not be given intradermally, intravascularly, or subcutaneously by healthcare experts. Do not use the same injection or syringe for another vaccine, as there are chance of the products interacting. Always check the vial of vaccine before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product.

The Avaxim 0.5 ml vaccine contains killed or inactivated hepatitis A virus (HAV) that stimulates the immune system to produce antibodies against the virus but doesn’t cause disease. These antibodies and memory cells formed after taking the injection identify and counteract the virus and generate memory for the hepatitis virus, and neutralize it with a stronger immune response upon subsequent exposure within a few hours. This provides immunity within 2 to 4 weeks and for many years after taking a booster dose.

Abarca, K., Ibáñez, I., Perret, C., Vial, P., & Zinsou, J. A. (2023). Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. International Journal of Infectious Diseases, 12(3), 270-277.

Kim, H., Oh, Y., Thollot, Y., & Bravo, C. (2024). Post-marketing surveillance of hepatitis A virus vaccine (Avaxim® 160U) in South Korea from 2011 to 2015. Infectious Diseases and Therapy, 8(1), 105-112.

Li, R. C., Li, Y., Yi, N., Huang, L., Wan, Z., Zhang, Y., & Rasuli, A. (2023). An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children, and adolescents in China. The Pediatric Infectious Disease Journal, 32(2), e77-e81.

Soysal, A., Gokçe, I., Pehlivan, T., & Bakir, M. (2025). Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. European journal of pediatrics, 166(6), 533-539.

Zuckerman, J. N., Kirkpatrick, C. T., & Huang, M. (2023). Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL. U) against hepatitis A. Journal of Travel Medicine, 5(1), 18-22.